Cancer Control最新文献

{"title":"Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study.","authors":"Akif Doğan, Sedat Yıldırım, Hande Nur Erölmez, Goncagül Akdağ, Hacer Şahika Yıldız, Zeynep Yüksel Yaşar, Heves Sürmeli, Nurullah İlhan, Özlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yıldırım, Nedim Turan, Mahmut Gümüş","doi":"10.1177/10732748261432273","DOIUrl":"10.1177/10732748261432273","url":null,"abstract":"<p><p>IntroductionThe Cancer Inflammation Prognostic Index (CIPI) is a composite biomarker that integrates carcinoembryonic antigen (CEA), neutrophil, and lymphocyte counts to reflect both tumor burden and systemic inflammation. Although CIPI has demonstrated prognostic value in early-stage and previously treated metastatic colorectal cancer, its role in untreated, de novo metastatic colon cancer remains unclear.MethodsThis multicenter, retrospective cohort study included 287 patients diagnosed with de novo metastatic colon cancer between 2010 and 2023. CIPI was calculated by multiplying serum CEA by the neutrophil-to-lymphocyte ratio, and the optimal cutoff value for overall survival (OS) was determined using receiver operating characteristic (ROC) curve analysis. Patients were stratified into low- and high-CIPI groups based on this threshold.ResultsThe median follow-up period was 4.0 years, during which 202 patients (70.4%) died. The optimal CIPI cutoff value for OS was 86.09. Median OS was significantly shorter in the high-CIPI group compared with the low-CIPI group (36.0 vs 14.5 months, p < 0.001). In multivariable Cox regression analysis, a high CIPI remained an independent prognostic factor for OS (hazard ratio, 2.29; 95% confidence interval, 1.65-3.17; p < 0.001). In a separate multivariable model, elevated CEA was also independently associated with poorer overall survival.ConclusionCIPI independently predicts overall survival in patients with de novo metastatic colon cancer. Its simplicity, cost-effectiveness, and derivation from routine laboratory data make it a practical and promising tool for baseline risk stratification and individualized follow-up planning.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261432273"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12961104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidity Level and Risk of 90-day and 18-month Complications Among Patients Undergoing Radical Prostatectomy for Prostate Cancer in the Military Health System.","authors":"Yvonne L Eaglehouse, Christian Dide-Agossou, Sarah Darmon, Sean Q Kern, Molly R Oroho, Andrea A Almeida, Craig D Shriver, Kangmin Zhu","doi":"10.1177/10732748261420506","DOIUrl":"10.1177/10732748261420506","url":null,"abstract":"<p><p>IntroductionProstate cancer is frequently diagnosed at ages when men may also have comorbidity. Access to care may influence both comorbidity management and cancer treatment and recovery. We examined the association between comorbidity and postoperative outcomes among men with prostate cancer in the universal access Military Health System (MHS).MethodsWe identified a cohort of men diagnosed with non-metastatic prostate adenocarcinoma from 2001-2014 who received radical prostatectomy (RP) within 1 year of diagnosis in the MilCanEpi database, which links the Department of War Cancer Registry and MHS Data Repository. We used ICD-9 diagnosis codes to capture 90-day postoperative general and genitourinary (GU) complications and hospital readmissions; and 18-month postoperative GU complications. Poisson regression estimated the adjusted risk ratios (ARRs) and 95% confidence intervals (CIs) for the outcomes associated with comorbidity (0, 1-2, or ≥3) measured using the Elixhauser Index.ResultsThe study included 5645 men with non-metastatic prostate cancer (mean age 57.9 ± 7.7 years) who received RP; 39.9% of patients had no comorbidity, 43.9% had 1-2 conditions, and 16.2% had ≥3 conditions. Patients with ≥3 comorbidities had statistically significant higher risks of 90-day general (ARR = 1.88, 95% CI = 1.34, 2.64) and GU (ARR = 1.20, 95% CI = 1.06, 1.36) complications and hospital readmission (ARR = 1.59, 95% CI = 1.12, 2.26) relative to men with no comorbidity. At 18-month post-RP, men with 1-2 comorbidities (ARR = 1.19, 95% CI = 1.05, 1.35) and ≥3 comorbidities (ARR = 1.32, 95% CI = 1.13, 1.55) had statistically significant higher risk of measured GU complications relative to men with no comorbidity.ConclusionsIn the MHS, higher comorbidity was associated with an increased risk of 30-day and 18-month complications and 90-day readmissions following RP for prostate cancer. This study identifies a need for risk management strategies to reduce complication rates among men with higher comorbidity levels diagnosed with prostate cancer and treated by RP.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261420506"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146020345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors.","authors":"Rosj Gallicchio, Mariarita Milella, Alessia Giordano, Mauro Cives, Rebecca Storto, Anna Nardelli, Giovanni Calice, Matteo Landriscina, Giovanni Storto","doi":"10.1177/10732748251413808","DOIUrl":"10.1177/10732748251413808","url":null,"abstract":"<p><p>IntroductionThe somatostatin receptor (SSTR) standardized uptake value (SUVmax_sstr) obtained by [⁶⁸Ga]Ga-edotreotide positron emission tomography-computed tomography ([⁶⁸Ga]Ga-SSTR PET/CT) helps recognize patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are at a high risk for adverse outcomes. This observational cohort study was conducted to verify whether the SSTR representative tumor volume (RTV_sstr) can provide incremental prognostic information over conventional PET/CT parameters in patients with metastatic disease.MethodsWe retrospectively evaluated patients (48% female) with metastatic GEP-NETs who underwent [⁶⁸Ga]Ga-SSTR PET/CT between January 2022 and November 2023. The mean SUVmax_sstr, mean RTV_sstr (cm³; 42% threshold), and total RTV_sstr were recorded. Thereafter, patients were followed up for 22.9 (range: 8-42) months. The PET/CT results were compared to the progression free survival (PFS).ResultsSixty patients (59 ± 5 years) were enrolled. Only the mean and total RTV_sstr values were predictive in the multivariate analysis. Kaplan-Meier survival analysis for both the mean and total RTV_sstr demonstrated a significantly better PFS in patients presenting with lower than greater values (<i>P</i> = 0.001 and <i>P</i> = 0.007, respectively; log-rank test). SUVmax_sstr was not appropriate for predicting PFS.ConclusionThe mean or total RTV_sstr represents a valuable volumetric parameter able to predict outcomes in patients with GEP-NETs that are metastatic at onset. The degree of the SSTR representative tumor burden, rather than the maximal SSTR representation at single voxel, has a predominant value for influencing the response to therapy in this cohort.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748251413808"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Increase of Early-Onset Colorectal Cancer: New Insights and Emerging Hypotheses.","authors":"Isaac Lee, Ezra Bernstein, Benjamin Lebwohl, Alfred I Neugut","doi":"10.1177/10732748261432271","DOIUrl":"10.1177/10732748261432271","url":null,"abstract":"<p><p>Rising rates of early-onset colorectal cancer have been noted worldwide. This commentary addresses possible causes of this trend and opportunities for intervention.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261432271"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147366965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age at Breast Cancer Diagnosis and Short-Term Postoperative Outcomes for Women Treated in a Universal Health System.","authors":"Gabrielle Falco, Sarah Darmon, Matthew Nealeigh, Robert W Krell, Craig D Shriver, Kangmin Zhu, Yvonne L Eaglehouse","doi":"10.1177/10732748261423266","DOIUrl":"10.1177/10732748261423266","url":null,"abstract":"<p><p>IntroductionSurgery is an essential component of breast cancer treatment. Surgical complications may impact receipt of adjuvant therapy and long-term outcomes. Differences in insurance coverage and access to care by patient age in the general U.S. population may affect breast cancer diagnosis and surgery and thus age comparisons in research. We compared postoperative outcomes following breast cancer surgery between age groups in the U.S. Military Health System, which provides beneficiaries access to comprehensive care across the lifespan.MethodsWe identified women aged ≥18 years with stage I-III breast cancer diagnosed from 2001 to 2014 undergoing surgery without reconstruction in the MilCanEpi database. Multivariable Poisson regression estimated the adjusted risk ratios (ARRs) with 95% confidence intervals (CIs) in association with age at diagnosis (18-39, 40-49, 50-64, and ≥65) for 30-day general and breast complications (surgical site infection, seroma, hematoma, or lymphedema), reoperation, and hospital readmission while controlling for potential confounders.ResultsThe study included 7835 women who were 18-39 (9.2%), 40-49 (23.6%), 50-64 (42.7%), and ≥65 (24.5%). The overall risk of general or breast complications did not differ significantly by age when controlled for demographic, tumor, and treatment variables. However, women aged 40-49 had a statistically increased adjusted risk of seroma (ARR = 1.50; 95% CI = 1.03-2.18) compared to women aged 50-64. No significant age-related differences were observed for reoperation or hospital readmission after adjustment.ConclusionIn the Military Health System, the overall risk of 30-day postoperative complications and hospital readmissions were not statistically different by age after adjustment for clinical and demographic factors. The findings support that surgical decision-making continue to prioritize tumor characteristics, comorbidity burden, and other clinical factors rather than age alone when assessing perioperative risk.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261423266"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12881331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) - Cohort Description.","authors":"Darren R Brenner, Xuanhao Feng, Courtney Maxwell, John M Hutchinson, Chantelle Carbonell, Reynaldo Nambayan, Linda Rabeneck, Jill Tinmouth, Nauzer Forbes, Steven J Heitman, Khara M Sauro, Colleen Cuthbert, Dylan E O'Sullivan, Robert J Hilsden","doi":"10.1177/10732748251413334","DOIUrl":"10.1177/10732748251413334","url":null,"abstract":"<p><p>IntroductionTherapeutic intervention with chemopreventive agents (CPA) represents a promising avenue for cancer prevention; however, additional data on patient adherence are needed. We developed the Colorectal Cancer Chemoprevention Acceleration Platform (CRC-CHAMP) and examined the feasibility of real-world CPA intervention in persons with an increased risk for CRC. Herein, we describe the recruitment, uptake, and adherence within this pilot study.MethodsFor this single-arm prospective pilot study (NCT05402124), we recruited individuals from the Forzani and MacPhail Colon Cancer Screening Centre (CCSC) in Calgary, Alberta, Canada. Eligible individuals were between the ages of 50-59 and had a history of high-risk adenomatous polyps diagnosed at the CCSC in the preceding 12 months. After consenting, each participant was provided open-label acetylsalicylic acid (ASA) at 81 mg every day for 90 days. Participants were contacted by telephone every 30 days to collect current adherence (primary outcome) and occurrence of any adverse events (secondary outcome).ResultsThroughout recruitment, 823 potential participants were identified, with 69 (53.1%) being eligible and 67 (51.5%) finally enrolling in the study. The median age of the participants was 56 yr. At the follow-ups, 60 participants (89.6%) were adherent at 30 days, 54 participants (80.6%) were adherent at 60 days, and 55 (82.1%) participants were adherent at 90 days. A total of 9 (13.4%) participants experienced minor adverse events likely unrelated to the ASA.ConclusionParticipants recruited to this pilot study had a high level of adherence throughout the 90-day period with minimal side effects. Challenges to recruitment included low response rate by mail and a high number of those contacted already taking non-steroidal anti-inflammatory drugs. This study suggests that individuals post-polypectomy of large polyp may be interested in CRC chemoprevention. Additionally, this study provides a framework for future evaluation of additional therapeutic interventions.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748251413334"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asian Burden of Liver Cancer 1990-2021 and Predictions to 2040: An Analysis of the Global Burden of Disease Study 2021.","authors":"Liandong Chen, Weibo Zheng, Haojie Ying, Xinyue Chen, Han Yan, Binzhe Zhou, Yuyuan Sun, Qihui Shao, Hanyu Xu, Bowen Jin, Haonan Jin, Bin Fu","doi":"10.1177/10732748261446367","DOIUrl":"10.1177/10732748261446367","url":null,"abstract":"<p><p>BackgroundLiver cancer (LivCa) is one of the most prevalent malignancies globally, and can result from viral hepatitis, non-alcoholic steatohepatitis (NASH), and alcohol use. LivCa is of increasing concern in Asia, but the burden of etiology-specific LivCa and future projections remain to be elucidated.MethodsWe extracted the incidence, mortality, and disability-adjusted life years (DALYs) of LivCa across Asia and in 34 Asian countries in 1990-2021 from the Global Burden of Disease Study 2021 (GBD 2021). We then calculated their estimated annual percentage change (EAPC) and percentage variation to quantify the changes in the burden of LivCa. The association of the level of social development with LivCa burden was explored using the sociodemographic index (SDI). Moreover, the trend of the epidemiology of LivCa burden in Asia from 2022 to 2040 was predicted using the Bayesian age-period-cohort (BAPC) model.ResultsOverall, the age-standardized incidence, mortality, and DALYs rates of LivCa in Asia showed a general declining trend, with EAPCs of -0.47, -0.73, and -1.14, respectively. Notably, hepatitis B virus remained the predominant cause. However, the burdens attributed to non-alcoholic steatohepatitis and alcohol use increased significantly, while that of hepatoblastoma decreased. Regarding demographic distribution, the highest disease burden was observed among males and the elderly population aged 85-94 years. Geographically, Nepal, Taiwan (Province of China), India, and Malaysia contributed most substantially to the increasing burden. In terms of risk factors, high BMI and alcohol use were prominent in Central Asia, whereas smoking was a key factor in East and Southeast Asia. Additionally, a positive correlation was observed between the SDI and the burden of LivCa. Finally, projections from the BAPC model indicated a persistent decline in the burden of LivCa from 2022 to 2040.ConclusionsDespite the overall decreasing trend, targeted strategies addressing etiology-specific risks and regional disparities are urgently needed to further reduce the future burden of LivCa in Asia.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261446367"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147786755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers and Facilitators of Programmatic HPV Testing: Lessons Learnt From Two In-Depth Provincial Case Studies Ten Years After the Jujuy Demonstration Project in Argentina.","authors":"Melisa Paolino, Partha Basu, Eric Lucas, Mauricio Cucchiaro, Evangelina Melnik, Mariela Nieva, Natalia Martiarena, Marcelo Ríos, Rosa Laudi, Silvina Arrossi","doi":"10.1177/10732748261446046","DOIUrl":"https://doi.org/10.1177/10732748261446046","url":null,"abstract":"<p><p>IntroductionAchieving the global goal of cervical cancer elimination faces major challenges, particularly in ensuring the large-scale and sustained implementation of proven technologies. In Argentina, HPV testing as primary screening was introduced through the Jujuy Demonstration Project (JDP) in 2012. The aim of this study is to analyze barriers and facilitators of the implementation of HPV testing in two provinces-Jujuy, and Catamarca-a decade after the JDP's completion.MethodsWe carried out a descriptive in-depth case study using a mixed-method approach, using qualitative and quantitative methods. Data were collected through participant observations in health services, semi-structured interviews with key informants, analysis of secondary sources, and program indicators. Barriers and facilitators were analyzed using an adapted Health System Framework focusing on four key dimensions: stewardship, organizational capacity, financing, and technology.ResultsRegarding stewardship, reduced technical support and monitoring from the National Program emerged as significant barrier. About financing, the most critical obstacle was the national interruption in the provision of HPV tests. Although both provinces have initiated procedures to purchase tests using provincial funds, this process was constrained by limited financial resources and competing priorities. Finally, regarding organizational capacity, challenges persisted in maintaining laboratory centralization, sustaining the offer of self-collection, and fully utilizing information systems for program monitoring. Facilitators related to stewardship included the stability of human resource in both provinces and the long-standing institutional recognition and leadership of provincial program staff. Sustained adherence to national guidelines and the existence of provincial resolutions were key enablers of continuity. In addition, acceptability of the technology remained high, with HPV testing continuing to be widely accepted in both provinces.ConclusionsOur findings reveal barriers and facilitators in the implementation ten years after JDP finalization, providing valuable lessons for scaling up HPV-based screening in national cancer control programs.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261446046"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.","authors":"Ali Kaan Güren, Nazım Can Demircan, Murat Sarı, Osman Köstek, İbrahim Vedat Bayoğlu","doi":"10.1177/10732748261451083","DOIUrl":"https://doi.org/10.1177/10732748261451083","url":null,"abstract":"<p><p>IntroductionTrastuzumab deruxtecan (T-DXd)-induced interstitial lung disease/pneumonitis (ILD) represents a clinically significant and potentially fatal toxicity. Discrepancies exist regarding its reported frequency and severity between clinical trials (CTs) and real-world data (RWD). This meta-analysis aims to evaluate the incidence of T-DXd-related ILD and investigate its differences between CTs and RWD.MethodsA systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Databases were searched from their inception through January 2026. CTs and real-world studies reporting T-DXd-related ILD were included in the analysis. Pooled incidences for all-grade, grade ≥3, and fatal ILD were calculated using random-effects models. Subgroup analyses comparing CTs and RWD, and meta-regression analyses for relevant outcomes were performed.ResultsThirty-five studies (19 CTs, 16 RWD) including 6840 patients were analyzed. The pooled incidence was 8.8% for all-grade ILD, 1.6% for grade ≥3 ILD, and 0.26% for fatal ILD. RWD was independently associated with lower reported rates of all-grade and fatal ILD, while prior lines of therapy were the main predictor of grade ≥3 ILD.ConclusionILD risk with T-DXd differs by severity and data source. Vigilant monitoring is essential, particularly in heavily pretreated patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748261451083"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147857493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Co-Creating Community-Living Interventions for Sustainable Cancer Control Programs: Meeting the Community Where They Are to Address Cancer Burden.","authors":"Folakemi T Odedina, Hayley Thompson, Kimlin Tam Ashing","doi":"10.1177/10732748251414201","DOIUrl":"10.1177/10732748251414201","url":null,"abstract":"<p><p><b>Background:</b> While much of cancer research has historically centered on innovations within clinical or laboratory settings, most of the factors shaping equity in cancer outcomes reside outside hospital walls-in neighborhoods, workplaces, and community networks. This reality underscores the need for community-involved and community-living interventions: <i>programs co-designed and delivered within communities to meet people where they live, work, and socialize</i>. Such interventions hold the greatest promise for sustainability because they are embedded in the daily lives, cultures, and resources of the populations they serve. <b>Methods:</b> This special collection brings together research that illuminates the power of community-centered and community co-led strategies for prevention, early detection, treatment, and survivorship across diverse settings. <b>Results:</b> The articles in this series illustrate how innovation, cultural humility, and local engagement can bridge persistent gaps in cancer care. <b>Conclusion:</b> Together, they highlight how communities themselves are essential partners in dismantling disparities and achieving lasting cancer control.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"33 ","pages":"10732748251414201"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}